PortalPublikationenLineage switch under blinatumomab treatment of relapsed comm...

Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement

Standard

Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement. / Zoghbi, Annabelle; Zur Stadt, Udo; Winkler, Beate; Müller, Ingo; Escherich, Gabriele.

in: PEDIATR BLOOD CANCER, Jahrgang 64, Nr. 11, 11.2017, S. 11.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Zoghbi, A, Zur Stadt, U, Winkler, B, Müller, I & Escherich, G 2017, 'Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement', PEDIATR BLOOD CANCER, Jg. 64, Nr. 11, S. 11. https://doi.org/10.1002/pbc.26594

APA

Zoghbi, A., Zur Stadt, U., Winkler, B., Müller, I., & Escherich, G. (2017). Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement. PEDIATR BLOOD CANCER, 64(11), 11. https://doi.org/10.1002/pbc.26594

Vancouver

Zoghbi A, Zur Stadt U, Winkler B, Müller I, Escherich G. Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement. PEDIATR BLOOD CANCER. 2017 Nov;64(11):11. https://doi.org/10.1002/pbc.26594

Bibtex

@article{bc4b339155c64522a382dbc7983bfa42,
title = "Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement",
abstract = "Blinatumomab is a bispecific T-cell engaging αCD19 antibody used in refractory or relapsed B-cell precursor acute lymphoblastic leukemia (ALL). Recently, lineage switch to a myeloid phenotype has been described following CD19 targeting treatment in three pediatric patients with mixed lineage leukemia (MLL) rearranged ALL. We report the case of a female who received blinatumomab for a first relapse of ALL without MLL alterations. She suffered from a second relapse early after hematopoietic stem cell transplantation and was treated with blinatumomab again. During this treatment, the leukemia lost CD19 expression as well as nearly all other B-cell markers, while still harboring the initial minimal residual disease marker, and switched to a myeloid phenotype.",
keywords = "Journal Article",
author = "Annabelle Zoghbi and {Zur Stadt}, Udo and Beate Winkler and Ingo M{\"u}ller and Gabriele Escherich",
note = "{\textcopyright} 2017 Wiley Periodicals, Inc.",
year = "2017",
month = nov,
doi = "10.1002/pbc.26594",
language = "English",
volume = "64",
pages = "11",
journal = "PEDIATR BLOOD CANCER",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "11",

}

RIS

TY - JOUR

T1 - Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement

AU - Zoghbi, Annabelle

AU - Zur Stadt, Udo

AU - Winkler, Beate

AU - Müller, Ingo

AU - Escherich, Gabriele

N1 - © 2017 Wiley Periodicals, Inc.

PY - 2017/11

Y1 - 2017/11

N2 - Blinatumomab is a bispecific T-cell engaging αCD19 antibody used in refractory or relapsed B-cell precursor acute lymphoblastic leukemia (ALL). Recently, lineage switch to a myeloid phenotype has been described following CD19 targeting treatment in three pediatric patients with mixed lineage leukemia (MLL) rearranged ALL. We report the case of a female who received blinatumomab for a first relapse of ALL without MLL alterations. She suffered from a second relapse early after hematopoietic stem cell transplantation and was treated with blinatumomab again. During this treatment, the leukemia lost CD19 expression as well as nearly all other B-cell markers, while still harboring the initial minimal residual disease marker, and switched to a myeloid phenotype.

AB - Blinatumomab is a bispecific T-cell engaging αCD19 antibody used in refractory or relapsed B-cell precursor acute lymphoblastic leukemia (ALL). Recently, lineage switch to a myeloid phenotype has been described following CD19 targeting treatment in three pediatric patients with mixed lineage leukemia (MLL) rearranged ALL. We report the case of a female who received blinatumomab for a first relapse of ALL without MLL alterations. She suffered from a second relapse early after hematopoietic stem cell transplantation and was treated with blinatumomab again. During this treatment, the leukemia lost CD19 expression as well as nearly all other B-cell markers, while still harboring the initial minimal residual disease marker, and switched to a myeloid phenotype.

KW - Journal Article

U2 - 10.1002/pbc.26594

DO - 10.1002/pbc.26594

M3 - SCORING: Journal article

C2 - 28453885

VL - 64

SP - 11

JO - PEDIATR BLOOD CANCER

JF - PEDIATR BLOOD CANCER

SN - 1545-5009

IS - 11

ER -